<strong>Purpose:</strong> This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT scans in staging breast carcinoma. <strong>Materials and Methods:</strong> A descriptive...<strong>Purpose:</strong> This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT scans in staging breast carcinoma. <strong>Materials and Methods:</strong> A descriptive study on 46 patients who were diagnosed with breast carcinoma in Hanoi Oncology Hospital, Vietnam from June 2019 to June 2021. Those patients underwent <sup>18</sup>F-FDG PET/CT scans for pre-treatment staging. <strong>Results:</strong> There was a positive correlation between the size of primary tumors and their SUV (p < 0.0001, r = 0.759). The mean SUV was reported to be 2.5 for tumors under 2 cm, 5.89 for tumors from 2 - 5 cm, 13.6 for tumors above 5 cm, and 8.23 for skin invasive lesions. In terms of regional lymph node metastasis detection, the sensitivity and specificity of <sup>18</sup>F-FDG PET/CT were 75% and 100%, respectively. The rate of distant metastasis detection was 15.2% (7/46 patients). Metastatic lesions were found in bone, lungs, liver, and lymph nodes. There was a significant difference in SUV among organs (p < 0.001), with the highest SUV found in bone metastasis. The rates of stage I, II, III and IV diagnosed after PET/CT are 8.7%;45.7%;30.4% and 15.2% respectively, compared to 10.9%;54.3%;32.6%;2.2% before taking <sup>18</sup>F-FDG PET/CT. After PET/CT, 17.4% patients (8/46) had their treatment plan changed. <strong>Conclusions: </strong><sup>18</sup>F-FDG PET/CT plays an important role in staging breast carcinoma. Determining accurately the breast carcinoma stage by <sup>18</sup>F-FDG PET/CT could help alter treatment strategy to best suit with patients, and avoid unnecessary surgery.展开更多
Background：Early diagnosis assumes a vital role in an effective treatment of Alzheimer＇s disease （AD）.Most of the current studies can only make anAD diagnosis after the manifestation of typical clinical symptoms.T...Background：Early diagnosis assumes a vital role in an effective treatment of Alzheimer＇s disease （AD）.Most of the current studies can only make anAD diagnosis after the manifestation of typical clinical symptoms.The present study aimed to investigate typical and other biomarkers of AD to find a possible early biomarker.Methods：A total of 14 5XFAD mice （at 3 and 6 months old）,with 14 age-matched wild-type （WT） mice as control,were enrolled in this case-control study.Morris water maze test was performed to evaluate the cognitive function;buried food pellet test and olfactory maze test were employed to investigate the olfactory function;immunofluorescence to detect amyloid deposition and positron emission tomography to examine 2-deoxy-2-（18F） fluoro-D-glucose （[18F]-FDG） uptake in the hippocampus and cerebral cortex.Results：With the increasing age,cognitive performance （P =0.0262） and olfactory function were significantly deteriorated （day 1 P =0.0012,day 2 P =0.0031,day 3 P =0.0160,respectively） and the （18F）-FDG uptake was markedly decreased in multi-cerebral regions including the olfactory bulb （P 〈 0.0001）,hippocampus （P =0.0121）,and cerebral cortex （P 〈 0.0001）.Of note,in 3-month-old 5XFAD mice,a significant decline of （18F）-FDG uptake in the olfactory bulb was found when compared with that of age-matched WT mice （P =0.023） while no significant difference was present when the uptakes in other cerebral regions were compared.Conclusions：The decline of （18F）-FDG uptake in the olfactory bulb occurs earlier than other incidents,serving as an earlier in vivo biological marker of AD in 5XFAD mice and making early diagnosis of AD possibly.展开更多
文摘<strong>Purpose:</strong> This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT scans in staging breast carcinoma. <strong>Materials and Methods:</strong> A descriptive study on 46 patients who were diagnosed with breast carcinoma in Hanoi Oncology Hospital, Vietnam from June 2019 to June 2021. Those patients underwent <sup>18</sup>F-FDG PET/CT scans for pre-treatment staging. <strong>Results:</strong> There was a positive correlation between the size of primary tumors and their SUV (p < 0.0001, r = 0.759). The mean SUV was reported to be 2.5 for tumors under 2 cm, 5.89 for tumors from 2 - 5 cm, 13.6 for tumors above 5 cm, and 8.23 for skin invasive lesions. In terms of regional lymph node metastasis detection, the sensitivity and specificity of <sup>18</sup>F-FDG PET/CT were 75% and 100%, respectively. The rate of distant metastasis detection was 15.2% (7/46 patients). Metastatic lesions were found in bone, lungs, liver, and lymph nodes. There was a significant difference in SUV among organs (p < 0.001), with the highest SUV found in bone metastasis. The rates of stage I, II, III and IV diagnosed after PET/CT are 8.7%;45.7%;30.4% and 15.2% respectively, compared to 10.9%;54.3%;32.6%;2.2% before taking <sup>18</sup>F-FDG PET/CT. After PET/CT, 17.4% patients (8/46) had their treatment plan changed. <strong>Conclusions: </strong><sup>18</sup>F-FDG PET/CT plays an important role in staging breast carcinoma. Determining accurately the breast carcinoma stage by <sup>18</sup>F-FDG PET/CT could help alter treatment strategy to best suit with patients, and avoid unnecessary surgery.
基金grants from the National Natural Science Foundation of China （No. 81171216 and No. 91232709）, and the Key Clinical Specialty Discipline Construction Program of Fujian and Nation, China.
文摘Background：Early diagnosis assumes a vital role in an effective treatment of Alzheimer＇s disease （AD）.Most of the current studies can only make anAD diagnosis after the manifestation of typical clinical symptoms.The present study aimed to investigate typical and other biomarkers of AD to find a possible early biomarker.Methods：A total of 14 5XFAD mice （at 3 and 6 months old）,with 14 age-matched wild-type （WT） mice as control,were enrolled in this case-control study.Morris water maze test was performed to evaluate the cognitive function;buried food pellet test and olfactory maze test were employed to investigate the olfactory function;immunofluorescence to detect amyloid deposition and positron emission tomography to examine 2-deoxy-2-（18F） fluoro-D-glucose （[18F]-FDG） uptake in the hippocampus and cerebral cortex.Results：With the increasing age,cognitive performance （P =0.0262） and olfactory function were significantly deteriorated （day 1 P =0.0012,day 2 P =0.0031,day 3 P =0.0160,respectively） and the （18F）-FDG uptake was markedly decreased in multi-cerebral regions including the olfactory bulb （P 〈 0.0001）,hippocampus （P =0.0121）,and cerebral cortex （P 〈 0.0001）.Of note,in 3-month-old 5XFAD mice,a significant decline of （18F）-FDG uptake in the olfactory bulb was found when compared with that of age-matched WT mice （P =0.023） while no significant difference was present when the uptakes in other cerebral regions were compared.Conclusions：The decline of （18F）-FDG uptake in the olfactory bulb occurs earlier than other incidents,serving as an earlier in vivo biological marker of AD in 5XFAD mice and making early diagnosis of AD possibly.
